系统性红斑狼疮零激素与零用药的可能性

doi:10.35541/cjd.20190432

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (10): 849-853.doi: 10.35541/cjd.20190432

系统性红斑狼疮零激素与零用药的可能性

刘海波¹ 曹华² 桑红¹

¹东部战区总医院（原南京军区南京总医院）皮肤科，南京 210002；²上海交通大学医学院附属瑞金医院皮肤科 200025

收稿日期:2019-03-26 修回日期:2019-10-14 发布日期:2020-09-30
通讯作者: 桑红 E-mail:shzwqzsl@163.com
基金资助:
江苏省皮肤病学创新团队项目（CXTDA2017038）；中国博士后科学基金资助项目（2015T81134）

Possible discontinuation of glucocorticoids and complete withdrawal of therapy in patients with systemic lupus erythematosus

Liu Haibo¹, Cao Hua², Sang Hong¹

¹Department of Dermatology, General Hospital of Eastern Theater Command （previously named as Nanjing General Hospital of Nanjing Military Command）, Nanjing 210002, China; ²Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2019-03-26 Revised:2019-10-14 Published:2020-09-30
Contact: Sang Hong E-mail:shzwqzsl@163.com
Supported by:
Jiangsu Dermatology Innovation Team （CXTDA2017038）; China Postdoctoral Science Foundation （2015T81134）

摘要/Abstract

摘要： 【摘要】近年来，达标治疗策略在系统性红斑狼疮（SLE）治疗中取得了巨大进展。达标治疗理念认为，SLE患者治疗的主要目标是获得并保持临床缓解，如不能达到临床缓解，则以达到低疾病活动度为次要目标。达到治疗目标并维持一定时间后，则可尝试糖皮质激素逐渐减量，如有可能可以完全停用。在持续获得临床缓解的患者中，可继续尝试逐渐减停免疫抑制剂和抗疟药物。在保持低疾病活动度的患者中，则可尝试免疫抑制剂逐渐减量。达标治疗理念为SLE零激素与零用药指明了方向并提供了可能性。本文总结了SLE达标治疗的最新理念，探讨了该理念对SLE治疗中糖皮质激素、免疫抑制剂以及抗疟药减停的影响及指导意义。

关键词: 红斑狼疮, 系统性, 糖皮质激素类, 达标治疗, 临床缓解, 低疾病活动度, 零用药

Abstract: 【Abstract】 In recent years, great advances have been made in application of treat-to-target （T2T） strategy to the treatment of systemic lupus erythematosus （SLE）. In T2T strategy, it is suggested that the main target in SLE treatment should be the attainment and maintenance of clinical remission; if clinical remission cannot be achieved, low disease activity could be an alternative target; when the treatment target is achieved and maintained for a period, physicians can try to reduce and minimize glucocorticoids and, if possible, glucocorticoids should be withdrawn completely; in patients in sustained clinical remission, the next step would be to reduce and stop immunosuppressants and antimalarials; in patients in sustained low disease activity, the next step would be to reduce immunosuppressants. In sum, T2T strategy offers the direction and provides the possibility of discontinuation of glucocorticoids and complete withdrawal of therapy in patients with SLE. This review summarizes the new concept of T2T in SLE treatment, and discusses the effect and guiding significance of T2T on discontinuation of glucocorticoids, immunosuppressants and antimalarials.

Key words: Lupus erythematosus, systemic, Glucocorticoids, Treat-to-target, Clinical remission, Low disease activity, Withdrawal of therapy

刘海波曹华桑红. 系统性红斑狼疮零激素与零用药的可能性[J]. 中华皮肤科杂志, 2020,53(10):849-853. doi:10.35541/cjd.20190432

Liu Haibo, Cao Hua, Sang Hong. Possible discontinuation of glucocorticoids and complete withdrawal of therapy in patients with systemic lupus erythematosus[J]. Chinese Journal of Dermatology, 2020, 53(10): 849-853.doi:10.35541/cjd.20190432

参考文献 37

［1］	Mosca M, Boumpas D, Bruce IN, et al. Treat⁃to⁃target in systemic lupus erythematosus: where are we today?［J］. Clin Exp Rheumatol, 2012,30（Suppl.73）:S112⁃S115.
［2］	Mak A, Cheung MW, Chiew HJ, et al. Global trend of survival and damage of systemic lupus erythematosus: meta⁃analysis and meta⁃regression of observational studies from the 1950s to 2000s［J］. Semin Arthritis Rheum, 2012,41（6）:830⁃839. doi: 10.1016/j.semarthrit.2011.11.002.
［3］	van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat⁃to⁃target in systemic lupus erythematosus: recommendations from an international task force［J］. Ann Rheum Dis, 2014,73（6）:958⁃967. doi: 10.1136/annrheumdis⁃2013⁃205139.
［4］	Almalki AH, Alrowaie FA, Alhozali HM, et al. Remission and long⁃term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia［J］. Lupus, 2019,28（9）:1082⁃1090. doi: 10.1177/0961203319860584.
［5］	Fasano S, DPE M, Pierro L, et al. Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS （Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale） study［J］. Clin Rheumatol, 2019,38（2）:457⁃463. doi: 10.1007/s10067⁃018⁃4286⁃9.
［6］	Poomsalood N, Narongroeknawin P, Chaiamnuay S, et al. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus［J］. Lupus, 2019,28（10）:1189⁃1196. doi: 10.1177/ 0961203319862614.
［7］	Gatto M, Zen M, Iaccarino L, et al. New therapeutic strategies in systemic lupus erythematosus management［J］. Nat Rev Rheumatol, 2019,15（1）:30⁃48. doi: 10.1038/s41584⁃018⁃0133⁃2.
［8］	陆前进, 罗帅寒天. 系统性红斑狼疮的诊疗进展［J］. 中华皮肤科杂志, 2018,51（1）:1⁃4. doi: 10.3760/cma.j.issn.0412⁃4030. 2018.01.001.
［9］	Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus［J］. Lupus, 2010,19（8）:949⁃956. doi: 10.1177/0961203310366 572.
［10］	Doria A, Gatto M, Iaccarino L, et al. Value and goals of treat⁃to⁃target in systemic lupus erythematosus: knowledge and foresight［J］. Lupus, 2015,24（4⁃5）:507⁃515. doi: 10.1177/09612033145 59087.
［11］	Zen M, Bassi N, Nalotto L, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven⁃year follow⁃up study［J］. Clin Exp Rheumatol, 2012,30（6）:856⁃863.
［12］	van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE （DORIS）［J］. Ann Rheum Dis, 2017,76（3）:554⁃561. doi: 10. 1136/annrheumdis⁃2016⁃209519.
［13］	Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes［J］. Ann Rheum Dis, 2015,74（12）:2117⁃2122. doi: 10.1136/annrheumdis⁃2015⁃207347.
［14］	Zen M, Iaccarino L, Gatto M, et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients［J］. Ann Rheum Dis, 2017,76（3）:562⁃565. doi: 10.1136/annrheumdis⁃2016⁃210154.
［15］	Tsang⁃A⁃Sjoe MW, Bultink IE, Heslinga M, et al. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus［J］. Rheumatology （Oxford）, 2017,56（1）:121⁃128. doi: 10.1093/rheumatology/kew377.
［16］	Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State （LLDAS）［J］. Ann Rheum Dis, 2016,75（9）:1615⁃1621. doi: 10.1136/annrheu mdis⁃2015⁃207726.
［17］	Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission［J］. Ann Rheum Dis, 2018,77（1）:104⁃110. doi: 10.1136/annrheum dis⁃2017⁃211613.
［18］	Petri M, Magder LS. Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort［J］. Arthritis Rheumatol, 2018,70（11）:1790⁃1795. doi: 10.1002/art.40571.
［19］	Ruiz⁃Arruza I, Barbosa C, Ugarte A, et al. Comparison of high versus low⁃medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis［J］. Autoimmun Rev, 2015,14（10）:875⁃879. doi: 10.1016/j.autrev.2015.05.011.
［20］	Aringer M, Leuchten N, Fischer⁃Betz R. Tapering and termination of immunosuppressive therapy: systemic lupus erythematosus［J］. Z Rheumatol, 2017,76（1）:27⁃32. doi: 10.1007/ s00393⁃016⁃0258⁃0.
［21］	Lightstone L, Doria A, Wilson H, et al. Can we manage lupus nephritis without chronic corticosteroids administration?［J］. Autoimmun Rev, 2018,17（1）:4⁃10. doi: 10.1016/j.autrev.2017.11. 002.
［22］	Mosca M, Tani C, Aringer M. Withdrawal of therapy in non⁃renal systemic lupus erythematosus: is this an achievable goal?［J］. Clin Exp Rheumatol, 2013,31（Suppl.78）:S71⁃S74.
［23］	Drenkard C, Villa AR, Garcia⁃Padilla C, et al. Remission of systematic lupus erythematosus［J］. Medicine （Baltimore）, 1996, 75（2）:88⁃98. doi: 10.1097/00005792⁃199603000⁃00005.
［24］	Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long⁃term follow⁃up［J］. Nephrol Dial Transplant, 2006,21（6）:1541⁃1548. doi: 10. 1093/ndt/gfk073.
［25］	Euler HH, Schroeder JO, Harten P, et al. Treatment⁃free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide［J］. Arthritis Rheum, 1994,37（12）:1784⁃1794. doi: 10.1002/art.1780371212.
［26］	Moroni G, Longhi S, Giglio E, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis［J］. Clin Exp Rheumatol, 2013,31（Suppl.78）:S75⁃S81.
［27］	Moroni G, Raffiotta F, Ponticelli C. Remission and withdrawal of therapy in lupus nephritis［J］. J Nephrol, 2016,29（4）:559⁃565. doi: 10.1007/s40620⁃016⁃0313⁃6.
［28］	Pincus T, Castrejón I, Bergman MJ, et al. Treat⁃to⁃target: not as simple as it appears［J］. Clin Exp Rheumatol, 2012,30（Suppl. 73）:S10⁃S20.
［29］	Alvarado AS, Malvar A, Lococo B, et al. The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients［J］. Lupus, 2014,23（8）:840⁃847. doi: 10.1177/096120331351 8625.
［30］	Felten R, Sagez F, Gavand PE, et al. 10 most important contemporary challenges in the management of SLE［J］. Lupus Sci Med, 2019,6（1）:e000303. doi: 10.1136/lupus⁃2018⁃000303.
［31］	Mok CC. Is treat⁃to⁃target in lupus nephritis realistic in clinical practice?［J］. Curr Rheumatol Rev, 2019,15（1）:2⁃6. doi: 10. 2174/1573397114666180406100857.
［32］	Steiman AJ, Gladman DD, Ibañez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period［J］. Arthritis Care Res （Hoboken）, 2012,64（4）:511⁃518. doi: 10.1002/acr.21568.
［33］	Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus［J］. N Engl J Med, 1991,324（3）:150⁃154. doi: 10.1056/NEJM199101173240303.
［34］	Costedoat⁃Chalumeau N, Galicier L, Aumaître O, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial （PLUS Study）［J］. Ann Rheum Dis, 2013,72（11）:1786⁃1792. doi: 10.1136/annrheumdis⁃2012⁃202322.
［35］	Cunha C, Alexander S, Ashby D, et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?［J］. Nephrol Dial Transplant, 2018,33（9）:1604⁃1610. doi: 10.1093/ndt/gfx318.
［36］	Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity outcomes over 10 years in systemic lupus erythematosus［J］. Arthritis Care Res （Hoboken）, 2019,71（6）:822⁃828. doi: 10.1002/acr.23720.
［37］	刘海波, 刘芳, 桑红. 在皮肤学科指南中应用GRADE证据质量分级和推荐强度评价系统的意义［J］. 中华皮肤科杂志, 2018,51（9）:639⁃641. doi: 10.3760/cma.j.issn.0412⁃4030.2018. 09.001.

[1]	樊碧娆陈喜雪王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681.
[2]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[3]	申晨陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445.
[4]	罗帅寒天龙海陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372.
[5]	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组中华医学会皮肤性病学分会儿童学组中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志, 2022, 55(4): 281-288.
[6]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[7]	邹美熔汪盛. 疱疹样脓疱病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(10): 928-931.
[8]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[9]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[10]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[11]	渠莉田苏惠春程波. 特应性皮炎与系统性疾病相关性的研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 463-466.
[12]	谢波尉晓冬许爱娥林福全周妙妮. 系统糖皮质激素治疗进展期白癜风的疗效及相关因素研究[J]. 中华皮肤科杂志, 2021, 54(2): 139-144.
[13]	中国中西医结合学会皮肤性病专业委员会色素病学组. 白癜风诊疗共识（2021版）[J]. 中华皮肤科杂志, 2021, 54(2): 105-109.
[14]	中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021, 54(2): 116-121.
[15]	罗帅寒天龙海张桂英陆前进. 2019年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(2): 183-186.

系统性红斑狼疮零激素与零用药的可能性

Possible discontinuation of glucocorticoids and complete withdrawal of therapy in patients with systemic lupus erythematosus

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

Metrics

本文评价

推荐阅读 10